Status:
COMPLETED
Trial of a Novel Fibrinolytic (Alfimeprase) to Clear Thrombosed Vascular Access Devices
Lead Sponsor:
ARCA Biopharma, Inc.
Conditions:
Catheters, Indwelling
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This trial is for patients with a central venous catheter (a vascular access device) that is not functioning properly (unable to withdraw blood). The trial compares a new blood clot dissolving agent (...
Eligibility Criteria
Inclusion
- Subjects must:
- have a dysfunctional Central Venous Access Device (CVAD) defined as unable to withdraw 3 mL blood
- have had the device in place for \> 48 hours
- be clinically stable
- be 18 or older
- give informed consent
Exclusion
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
115 Patients enrolled
Trial Details
Trial ID
NCT00073515
Last Update
February 3 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cleveland Clinic Foundation
Cleveland, Ohio, United States